T helper 2 inhibitors in allergic contact dermatitis
Abstract
Clinical trials are currently underway to evaluate the benefit of dupilumab in treating allergic contact dermatitis (ACD). Dupilumab use has been reported to improve ACD reactions in some patients, but not all. Varying clinical responses to T helper 2 (TH2) inhibition challenge the classical view that ACD proceeds through a TH1-dominant pathway. Selective TH2 inhibitors, such as dupilumab, may attenuate ACD when the delayed hypersensitivity response is due to TH2-predominate activation; conversely, it may have no effect on ACD if it is elicited via TH1 or TH17 pathways. We hypothesize that allergen-specific T-cell responses and patient-specific factors both play an important role in determining which pathways are recalled in delayed hypersensitivity reactions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patient-specific factors also should be considered, as they could have an impact on the reliability of patch test findings after starting dupilumab.
“This finding suggests that patient-specific factors also should be considered, as this too could have an impact on the reliability of patch test findings after starting dupilumab.29”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [29]
The inconsistency in patch testing results after dupilumab may relate to the allergen-specific pathogenesis of ACD-one allergen may have a different response to the mechanism of dupilumab than another.
“This inconsistency in results may relate to the allergen-specific pathogenesis of ACD-one allergen may have a different response to the mechanism of dupilumab than another.28,29”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [29]
Cites
Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab
Zhu, G. A., Chen, J. K., Chiou, A., Ko, J., & Honari, G. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.01.023 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Ludwig, C. M., Krase, J. M., & Shi, V. Y.
- Affiliations
- University of Illinois Chicago (US)
- University of Arizona (US)
- Venue
- Dermatitis
- Publisher
- SAGE Publications
- Published
- 2020-06-03
- Volume
- 32
- Issue
- 1
- Pages
- 15-18
- ISSN
- 1710-3568 (ISSN-L)
- 2162-5220
- OpenAlex
- W3029768375
- Cited by
- 9
- References
- 1
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dermatitis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- allergic contact dermatitis, dupilumab, delayed-type hypersensitivity, Th1 response, Th17 response, allergen-specific T cell responses, patient factors, clinical trial results
- MeSH terms
- Allergens, Humans, Dermatitis, Allergic Contact, Th1 Cells, Th2 Cells, Th17 Cells, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
